Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BX-E001
- Development stage
- Preclinical
- Lead developer
- Baylx
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
BX-E001 is an allogenic, engineered human umbilical cord tissue-derived mesenchymal stem cell therapy candidate. It is being developed by Baylx for the treatment of advanced colon cancer and potentially other indications such as Crohn's disease and rheumatoid arthritis. The product leverages the regenerative and immunomodulatory properties of mesenchymal stem cells to replace or repair damaged tissues, aiming to address diseases that are refractory to conventional therapies. As of the latest updates, its highest development status is preclinical.
Beyond the preview
Go deeper on BX-E001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BX-E001.